The immune checkpoint inhibitor (ICI) therapy targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), anti-programmed cell death protein-1 (PD-1), and programmed cell death-ligand 1 (PD-L1) were potential activity against HCC and manageable safety in clinical trial [7]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.